ANIPCIK 1023024

ANI PHARMACEUTICALS INC

EDGAR filings

Customers

None disclosed

Suppliers

1 disclosed

Top supplier share

54.8%

of EYPT revenue · FY to 2025-12-31

Top supplier by $

$17.2M

EYPT · FY to 2025-12-31

Latest period

Dec 31, 2025

10-K filed 2026-03-05

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 1

Companies that disclose ANIP as a major customer, as a share of their own revenue. 1 active, 0 lapsed.

Company	% of their revenue	Est. $ from ANIP	Period	Trend	Status	Source
EYPT EyePoint, Inc.	54.8%	$17.2M	FY 2025-12-31	−38.8pp	Active	10-K 2026-03-05
For the year ended December 31, 2025 revenues from ANI Pharmaceuticals, Inc. (ANI), formerly Alimera Sciences, Inc. and SWK Funding LLC (SWK), accounted for 54.8% and 40.4% of total revenues, respectively.As of December 31, 2024, accounts receivable from ANI accounted for 72.3% and accounts receivable from OncoSil Medical Ltd. accounted for 16.5% of total accounts receivable, respectively. 10-K filed 2026-03-05 Period FY 2025-01-01 to 2025-12-31 (54.8%), FY 2024-01-01 to 2024-12-31 (93.6%)Accession 0001193125-26-093917 For the year ended December 31, 2019, revenues from the Specialty Distributor, an affiliate of the 3PL, ASD Specialty Healthcare LLC, and Alimera Sciences accounted for 56.0%, 15.0%, and 10.0% of total revenues, respectively. 10-K filed 2021-03-12 Period FY 2019-01-01 to 2019-12-31 (10%)Accession 0001564590-21-012894

Alerts are coming

Get an email when ANIP's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.